Latest Eli Lilly and Company (LLY) Headlines Ca
Post# of 128
Posted On: 03/14/2014 2:11:36 AM
Latest Eli Lilly and Company (LLY) Headlines
Can Eli Lilly Continue its Bull Run?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 13, 8:30AM CDT
Investors in Eli Lilly had a disappointing 2013, as shares in the company gained just 5% while the S&P 500 rose by almost 32%. A key reason for the stock's underperformance was the generic drugs that ate...
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Eli Lilly Rises 1.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Mar 12, 3:52PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.12 to a high of $59.21. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $59.08 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.32% Gain
Comtex SmarTrend(R) - Wed Mar 12, 3:52PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.12 to a high of $59.21. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $59.08 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
Spend Management Industry Flocks to NextLevel 2014
Business Wire - Wed Mar 12, 8:01AM CDT
SciQuest, Inc. (NASDAQ:SQI), the largest pure-play provider of cloud-based business automation solutions for spend management, today announced that NextLevel 2014 once again broke an attendance record, drawing 725 attendees from more than 300 organizations. The three-day event, which has become the industry's largest conference solely dedicated to spend management and advanced sourcing, took place at the Gaylord Palms Resort and Conference Center and packed an agenda full of industry best practices, expert knowledge, and hands-on learning.
Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Insulin Delivery Devices Market is Expected to Grow at a CAGR of 8.5% During 2012-2017
M2 - Tue Mar 11, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rppmnp/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Forecast to 2017" report to their offering. 371 Million people had diabetes in 2012 and by 2030 this number is expected to rise to 552 Million. This finding by International Diabetes Federation (IDF) and similar results from studies done by organizations of repute like WHO, CDC, NHS etc. suggest that a huge patient population exists for the diabetes healthcare market. It is estimated that in 2011, around US$ 465 Billion were spent on healthcare expenditures related to diabetes. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In latest research study, Global Insulin Delivery Devices Market Forecast to 2017, the company's analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 8.8 Billion in 2012, is expected to grow at a CAGR of 8.5% during 2012-2017. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of delivery devices' market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth and its future outlook. This study leads to the proposition that innovation has huge scope in this field and its analysts have advertently elaborated some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche, Becton, Dickinson and Company that together account for more than 90% of the global market. Companies Mentioned: - Novo Nordisk - Eli Lilly - Medtronic - Becton Dickinson - Sanofi-Aventis - F. Hoffmann La Roche For more information visit http://www.researchandmarkets.com/research/rp...al_insulin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
How Will This Latest Setback Affect Eli Lilly?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 11, 8:30AM CDT
Still struggling to revive its drought of approvals, especially after staunchly refusing to succumb to the rest of Big Pharma's strategy of mergers and acquisitions, Eli Lilly suffered another setback for its diabetes pipeline this week when the...
The US Specialty Pharmaceutical Market Report: 2013 Edition
M2 - Tue Mar 11, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bkqqb/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2013 Edition" report to their offering. Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are used for treating such conditions meet all the three H's: High Cost, High Complexity and High Touch and they require extensive education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications. Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby additionally offering a business perspective for the biopharmaceutical companies. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players. The fierce competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing drugs, mail pharmacies and distributors. Company profiles of leading players are also presented in the report. Key Topics Covered 1. Overview 1.1 Specialty Pharmaceuticals Vs Traditional Drugs 1.2 Applications of Specialty Pharmaceuticals 1.3 Specialty Pharmacy Services 1.4 Specialty Product Distribution 1.5 Specialty Pharma Manufacturer Services 1.6 Value Proposition of Specialty Pharmacy 2. Market Size 2.1 Pharmaceutical Market 2.2 The US Specialty Pharmaceutical Market 3. Market Dynamics 3.1 Growth Drivers 3.2 Trends and Developments 3.3 Challenges 4. Competitive Landscape 4.1 Competition by Drugs 4.2 Competition by Mail Pharmacy 4.3 Competition by Specialty Distributor 5. Company Profiles 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology Companies Mentioned - Amgen - Eli Lilly and Company - Johnson & Johnson - Novo Nordisk - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/8b..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Pemetrexed Market, 2009-2018: A Multi-Targeted Antimetabolite Antitumor Drug
M2 - Mon Mar 10, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbcsqg/investigation) has announced the addition of the "Investigation Report on China Pemetrexed Market, 2009-2018" report to their offering. Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market. Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer. So far pemetrexed (brand name ""Alimta"") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion. In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013. Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field. Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day. From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company. By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China. Key Topics Covered: 1 Relevant Concepts of Pemetrexed 2 Market Overview of Pemetrexed in China, 2009-2013 3 Investigation on Sales Value of Pemetrexed in China, 2009-2013 4 Investigation on Market Share of Major Pemetrexed Manufacturers in China, 2009-2013 5 Investigation on Market Size of Pemetrexed by Dosage Form in China, 2009-2013 6 Reference Price of Pemetrexed Produced by Different Enterprises in China Hospital Market 7 Prospect of China Pemetrexed Market, 2014-2018 Companies Mentioned - Qilu Pharmaceutical Co., Ltd. - Hansoh Pharmaceutical - LILLY France - Dezhou Pharmaceutical Co., Ltd. - Nanjing Pharmaceutical Factory Co., Ltd. - Eli Lilly and Company - Nanjing Yadong Qitian Pharmaceutical Co., Ltd. - Jiangsu Aosaikang Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/lb...estigation
Investigation Report on China's Duloxetine Market, 2009-2018
M2 - Mon Mar 10, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnwg9t/investigation) has announced the addition of the "Investigation Report on China Duloxetine Market, 2009-2018" report to their offering. Depression is a common mood disorder that belongs to high-incidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors. According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a ""Century of Depression"". China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China. Since Eli Lilly and Company first launched duloxetine (brand name ""Cymbalta"") in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012. Through this report, the readers can acquire the following information: - Incidence of Depression in China - Market Share of Major Duloxetine Manufacturers in Sample Hospitals in China - Sales price of Duloxetine in Hospital Market in China - Production Status of Duloxetine Generic Drug in China - Major Duloxetine Manufacturers in China - Share of Duloxetine in Different Dosage Forms in China Hospital Market - Prospect of China Duloxetine Market The author recommends the report to the following: - Antidepressant APIs and Finished Product Manufacturers - Medical Institutions - Investors /Research Agencies Focusing on China Antidepressant Market Key Topics Covered: 1 Relevant Concepts of Duloxetine 2 Market Overview of Duloxetine in China 3 Investigation on Sales Value of Duloxetine in China, 2009-2013 4 Investigation on Market Share of Major Duloxetine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Duloxetine by Dosage Form in China, 2009-2013 6 Reference Price of Duloxetine in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Duloxetine Market, 2009-2013 8 Prospect of China Duloxetine Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/jn...estigation
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Pipeline Progress at Alkermes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 3:30PM CST
Alkermes announced that it has initiated a pivotal program to evaluate ALKS 5461.
The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 1.19% Sell Off
Comtex SmarTrend(R) - Thu Mar 06, 4:23PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.69 to a high of $59.92. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $58.81 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Can Eli Lilly Continue its Bull Run?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 13, 8:30AM CDT
Investors in Eli Lilly had a disappointing 2013, as shares in the company gained just 5% while the S&P 500 rose by almost 32%. A key reason for the stock's underperformance was the generic drugs that ate...
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Eli Lilly Rises 1.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Mar 12, 3:52PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.12 to a high of $59.21. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $59.08 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.32% Gain
Comtex SmarTrend(R) - Wed Mar 12, 3:52PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.12 to a high of $59.21. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $59.08 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
Spend Management Industry Flocks to NextLevel 2014
Business Wire - Wed Mar 12, 8:01AM CDT
SciQuest, Inc. (NASDAQ:SQI), the largest pure-play provider of cloud-based business automation solutions for spend management, today announced that NextLevel 2014 once again broke an attendance record, drawing 725 attendees from more than 300 organizations. The three-day event, which has become the industry's largest conference solely dedicated to spend management and advanced sourcing, took place at the Gaylord Palms Resort and Conference Center and packed an agenda full of industry best practices, expert knowledge, and hands-on learning.
Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Insulin Delivery Devices Market is Expected to Grow at a CAGR of 8.5% During 2012-2017
M2 - Tue Mar 11, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rppmnp/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Forecast to 2017" report to their offering. 371 Million people had diabetes in 2012 and by 2030 this number is expected to rise to 552 Million. This finding by International Diabetes Federation (IDF) and similar results from studies done by organizations of repute like WHO, CDC, NHS etc. suggest that a huge patient population exists for the diabetes healthcare market. It is estimated that in 2011, around US$ 465 Billion were spent on healthcare expenditures related to diabetes. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In latest research study, Global Insulin Delivery Devices Market Forecast to 2017, the company's analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 8.8 Billion in 2012, is expected to grow at a CAGR of 8.5% during 2012-2017. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of delivery devices' market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth and its future outlook. This study leads to the proposition that innovation has huge scope in this field and its analysts have advertently elaborated some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche, Becton, Dickinson and Company that together account for more than 90% of the global market. Companies Mentioned: - Novo Nordisk - Eli Lilly - Medtronic - Becton Dickinson - Sanofi-Aventis - F. Hoffmann La Roche For more information visit http://www.researchandmarkets.com/research/rp...al_insulin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
How Will This Latest Setback Affect Eli Lilly?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 11, 8:30AM CDT
Still struggling to revive its drought of approvals, especially after staunchly refusing to succumb to the rest of Big Pharma's strategy of mergers and acquisitions, Eli Lilly suffered another setback for its diabetes pipeline this week when the...
The US Specialty Pharmaceutical Market Report: 2013 Edition
M2 - Tue Mar 11, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bkqqb/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2013 Edition" report to their offering. Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are used for treating such conditions meet all the three H's: High Cost, High Complexity and High Touch and they require extensive education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications. Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby additionally offering a business perspective for the biopharmaceutical companies. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players. The fierce competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing drugs, mail pharmacies and distributors. Company profiles of leading players are also presented in the report. Key Topics Covered 1. Overview 1.1 Specialty Pharmaceuticals Vs Traditional Drugs 1.2 Applications of Specialty Pharmaceuticals 1.3 Specialty Pharmacy Services 1.4 Specialty Product Distribution 1.5 Specialty Pharma Manufacturer Services 1.6 Value Proposition of Specialty Pharmacy 2. Market Size 2.1 Pharmaceutical Market 2.2 The US Specialty Pharmaceutical Market 3. Market Dynamics 3.1 Growth Drivers 3.2 Trends and Developments 3.3 Challenges 4. Competitive Landscape 4.1 Competition by Drugs 4.2 Competition by Mail Pharmacy 4.3 Competition by Specialty Distributor 5. Company Profiles 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology Companies Mentioned - Amgen - Eli Lilly and Company - Johnson & Johnson - Novo Nordisk - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/8b..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Pemetrexed Market, 2009-2018: A Multi-Targeted Antimetabolite Antitumor Drug
M2 - Mon Mar 10, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbcsqg/investigation) has announced the addition of the "Investigation Report on China Pemetrexed Market, 2009-2018" report to their offering. Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market. Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer. So far pemetrexed (brand name ""Alimta"") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion. In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013. Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field. Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day. From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company. By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China. Key Topics Covered: 1 Relevant Concepts of Pemetrexed 2 Market Overview of Pemetrexed in China, 2009-2013 3 Investigation on Sales Value of Pemetrexed in China, 2009-2013 4 Investigation on Market Share of Major Pemetrexed Manufacturers in China, 2009-2013 5 Investigation on Market Size of Pemetrexed by Dosage Form in China, 2009-2013 6 Reference Price of Pemetrexed Produced by Different Enterprises in China Hospital Market 7 Prospect of China Pemetrexed Market, 2014-2018 Companies Mentioned - Qilu Pharmaceutical Co., Ltd. - Hansoh Pharmaceutical - LILLY France - Dezhou Pharmaceutical Co., Ltd. - Nanjing Pharmaceutical Factory Co., Ltd. - Eli Lilly and Company - Nanjing Yadong Qitian Pharmaceutical Co., Ltd. - Jiangsu Aosaikang Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/lb...estigation
Investigation Report on China's Duloxetine Market, 2009-2018
M2 - Mon Mar 10, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnwg9t/investigation) has announced the addition of the "Investigation Report on China Duloxetine Market, 2009-2018" report to their offering. Depression is a common mood disorder that belongs to high-incidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors. According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a ""Century of Depression"". China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China. Since Eli Lilly and Company first launched duloxetine (brand name ""Cymbalta"") in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012. Through this report, the readers can acquire the following information: - Incidence of Depression in China - Market Share of Major Duloxetine Manufacturers in Sample Hospitals in China - Sales price of Duloxetine in Hospital Market in China - Production Status of Duloxetine Generic Drug in China - Major Duloxetine Manufacturers in China - Share of Duloxetine in Different Dosage Forms in China Hospital Market - Prospect of China Duloxetine Market The author recommends the report to the following: - Antidepressant APIs and Finished Product Manufacturers - Medical Institutions - Investors /Research Agencies Focusing on China Antidepressant Market Key Topics Covered: 1 Relevant Concepts of Duloxetine 2 Market Overview of Duloxetine in China 3 Investigation on Sales Value of Duloxetine in China, 2009-2013 4 Investigation on Market Share of Major Duloxetine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Duloxetine by Dosage Form in China, 2009-2013 6 Reference Price of Duloxetine in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Duloxetine Market, 2009-2013 8 Prospect of China Duloxetine Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/jn...estigation
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Pipeline Progress at Alkermes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 3:30PM CST
Alkermes announced that it has initiated a pivotal program to evaluate ALKS 5461.
The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 1.19% Sell Off
Comtex SmarTrend(R) - Thu Mar 06, 4:23PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $58.69 to a high of $59.92. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $58.81 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
(0)
(0)Eli Lilly & Co. (LLY) Stock Research Links
Scroll down for more posts ▼